Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial.
about
Dipeptidyl Peptidase-4 Regulation of SDF-1/CXCR4 Axis: Implications for Cardiovascular DiseaseStimulating endogenous cardiac repairStrategies and Challenges to Myocardial Replacement TherapyStem Cell Therapy for the Heart: Blind Alley or Magic Bullet?Exploring pericyte and cardiac stem cell secretome unveils new tactics for drug discoveryRandomized Clinical Trials of Gene Transfer for Heart Failure with Reduced Ejection Fraction.Translation of Cardiac Myosin Activation with 2-deoxy-ATP to Treat Heart Failure via an Experimental Ribonucleotide Reductase-Based Gene TherapyMdivi-1 induced acute changes in the angiogenic profile after ischemia-reperfusion injury in female mice.CXCR7/p-ERK-Signaling Is a Novel Target for Therapeutic Vasculogenesis in Patients with Coronary Artery DiseaseA novel recombinant antibody specific to full-length stromal derived factor-1 for potential application in biomarker studies.Gene therapy for the treatment of heart failure: promise postponedVildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetes.Cardiovascular Gene Therapy: Past, Present, and Future.Current Methods in Cardiac Gene Therapy: Overview.Regenerative pharmacology: recent developments and future perspectives.The Role for Cardiovascular Remodeling in Cardiovascular Outcomes.Anti-inflammatory drugs as promising cardiovascular treatments.Concise Review: Mending a Broken Heart: The Evolution of Biological Therapeutics.Regulation of Pulmonary Vascular Smooth Muscle Contractility in Pulmonary Arterial Hypertension: Implications for Therapy.Ventricular Arrhythmia after Acute Myocardial Infarction: 'The Perfect Storm'Circulating Stromal Cell-Derived Factor 1α Levels in Heart Failure: A Matter of Proper Sampling.Introducing Genes to the Heart: All About Delivery.Angiogenic gene therapy in cardiovascular diseases: dream or vision?Anti-inflammatory therapies in myocardial infarction: failures, hopes, and challenges.Understanding Key Mechanisms of Exercise-Induced Cardiac Protection to Mitigate Disease: Current Knowledge and Emerging Concepts.Title: Therapeutic strategies utilising SDF-1α in ischaemic cardiomyopathy.Alcohol-Mediated Organ Damages: Heart and Brain.Cardiomyocyte-derived CXCL12 is not involved in cardiogenesis but plays a crucial role in myocardial infarction.SDF 1-alpha Attenuates Myocardial Injury Without Altering the Direct Contribution of Circulating Cells.Myocardial Injury as a New Target for Cell Therapy in Patients With Chronic Heart Failure: When Something Bad Is Actually Good?The promise of stromal cell-derived factor-1 in novel heart disease treatments.Evaluation of Multiple Biological Therapies for Ischemic Cardiac Disease.Using Acellular Bioactive Extracellular Matrix Scaffolds to Enhance Endogenous Cardiac Repair.Global position paper on cardiovascular regenerative medicine
P2860
Q26781269-E9EF171A-60DE-4BBB-8ECC-B7115D4FEDB8Q26781323-BF4A1117-4C17-4743-AA63-6E77BB22E5D5Q28068007-B5F52FC2-E867-4BA9-B862-ADCEE2ACBF0BQ28069300-A0CB2F37-7417-4767-8B62-A5F0BDF44C8AQ28073078-3E1A2723-4D8D-458A-A0A1-D66819D04FF0Q33727294-D8BF3465-6764-489C-AA56-E38F90F851D3Q33728779-E71AAC95-1001-49A8-8716-EBD6BE66FFF4Q33800230-5ED060FD-DAAD-4082-9400-8C7573B6A6D4Q36128553-8E308D1A-F98F-4538-A047-E4D6E78B0952Q36335874-0FC363A3-981B-4889-9E77-E00FC583A812Q36953151-4BE85E5E-98C0-4E8B-8416-E9F13D03351BQ37663425-EB241F18-04C6-47C1-A96C-57325B0DF393Q38733395-6D5C4FD4-35E0-4FB9-BB49-0700673EAE40Q38788217-3557A151-D22D-4C26-AF09-6E1F79A736E7Q38788701-8D08E389-621A-48E5-ACE6-5C2BBEF23BCFQ38867740-2AE3DED1-7C54-444B-AFBB-0BA4F936F8FEQ39051784-162D4671-00EE-4401-9902-668848DF99DAQ39149000-F70AD0C0-F1A4-4646-B7C8-14B508AE92BBQ41526246-B8A6CFED-3313-4001-BAAD-4CF2A10EF694Q42363085-8D5FCE1B-ACAE-46B6-AC28-5A093D7B311AQ43185050-6706C9EA-C36F-4787-9753-A0CD2675714BQ45863402-7C65404E-BB69-45A4-9EDE-B95EB4327507Q45863499-201CB0C8-69E6-4670-9177-DD3FFFFD11DEQ48113765-D0852FFE-2387-4ECD-A4C3-2B1BE7E2E57FQ49917356-08B9EFFC-ACC3-4054-BF5C-5B0325FC32A0Q50080437-6E59396D-F82A-41F7-9931-2D7A506ED446Q50318074-5A4A7624-102F-41DB-A8CC-F02F2E49CCF2Q50634547-EB172B86-0556-40CC-B010-3F02BE63A82EQ52731083-FFD708A2-69B7-447C-BE75-3E5157639BEBQ52766189-4FF60A25-47E1-41C1-B236-C74704E86C2EQ52837115-271D389F-E952-49B4-AB92-DB328ECE2F5CQ53104041-DC2786FF-787B-431E-8C3B-99BA185EBBC5Q55118363-20216DC2-3C1E-4604-B650-FE66B921CE96Q56985687-B1C29E99-7FF5-46AA-B6AC-E0B899E27548
P2860
Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Changes in ventricular remodel ...... -HF randomized Phase II trial.
@ast
Changes in ventricular remodel ...... -HF randomized Phase II trial.
@en
type
label
Changes in ventricular remodel ...... -HF randomized Phase II trial.
@ast
Changes in ventricular remodel ...... -HF randomized Phase II trial.
@en
prefLabel
Changes in ventricular remodel ...... -HF randomized Phase II trial.
@ast
Changes in ventricular remodel ...... -HF randomized Phase II trial.
@en
P2093
P2860
P921
P356
P1476
Changes in ventricular remodel ...... -HF randomized Phase II trial.
@en
P2093
Alexander T AuWerter
Eugene S Chung
Farrell O Mendelsohn
Francis Plat
Gregory Ewald
Jay Traverse
Joseph M Pastore
Julia Shin
Kevin H Silver
Leslie Miller
P2860
P304
P356
10.1093/EURHEARTJ/EHV254
P50
P577
2015-06-07T00:00:00Z